Prokidney (PROK) Cash & Equivalents (2021 - 2026)

Prokidney (PROK) has reported Cash & Equivalents for 6 consecutive years, with $181.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 113.76% year-over-year to $181.6 million in Q2 2026; TTM through Jun 2026 was $181.6 million, a 113.76% increase from a year earlier, with the FY2025 full-year figure at $108.5 million, up 9.5% from the prior year.
• Cash & Equivalents was $181.6 million for Q2 2026 at Prokidney, up from $101.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $506.3 million in Q3 2022 and troughed at $60.6 million in Q4 2023.
• A 5-year average of $183.7 million and a median of $108.3 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 2284.73% in 2022 and slumped 87.63% in 2023, its largest moves.
• Over 5 years, Cash & Equivalents stood at $490.3 million in 2022, then tumbled by 87.63% to $60.6 million in 2023, then jumped by 63.43% to $99.1 million in 2024, then grew by 9.5% to $108.5 million in 2025, then surged by 67.28% to $181.6 million in 2026.
• The last three Cash & Equivalents figures came in at $181.6 million (Q2 2026), $101.9 million (Q1 2026), and $108.5 million (Q4 2025), per Business Quant data.